Zila Expands International Market of Ester-C(R) in Europe; Gee Lawson, Limited, Signs Distributor Agreement
May 26 2006 - 8:30AM
Business Wire
Zila, Inc.'s (Nasdaq: ZILA), wholly-owned subsidiary, Zila
Nutraceuticals, Inc., has signed an agreement with Gee Lawson,
Limited, to distribute its Ester-C advanced vitamin C ingredient
throughout Europe. Gee Lawson had been representing Ester-C in the
United Kingdom prior to expanding its geography to cover most of
Europe. Zila also has a distribution agreement in place with
Naturkost for the Scandinavian region. "Gee Lawson has been a
long-time customer of Zila Nutraceuticals and has worked
extensively to impressively grow the market for Ester-C in the
United Kingdom. We're pleased to expand these efforts into other
European countries," said Douglas D. Burkett, Ph.D., Chairman,
Chief Executive Officer and President of Zila, Inc. "This
represents another step in the progress we're making in the
execution of Zila Nutraceuticals' aggressive international growth
plan." About Gee Lawson Founded in 1939, Gee Lawson is one of
Europe's leading ethical suppliers of raw materials for the food,
nutraceutical, vitamin, mineral and supplement industries.
Headquartered in London, Gee Lawson also has an office in
Switzerland as well as sales representatives located throughout
Europe. "We are extremely pleased to solidify this agreement with
Zila Nutraceuticals and look forward to expanding the market for
Ester-C in other European countries," said Jonathan Shorts,
managing director for Gee Lawson. About Ester-C Ester-C calcium
ascorbate/threonate is an advanced form of vitamin C. Unlike other
forms of vitamin C, Ester-C is non-acidic, so it's gentle on the
stomach. Ester-C is a readily absorbed form of vitamin C that helps
support immune health, heart health, joint health and vision. For
more information about Ester-C, visit www.ester-c.com. Ester-C is
the registered trademark of Zila Nutraceuticals, Inc. Information
and statements regarding dietary supplements have not been
evaluated by the Food and Drug Administration and are not intended
to diagnose, treat, cure, or prevent any disease. About Zila Zila,
Inc., headquartered in Phoenix, is an innovator in preventative
healthcare technologies and products, focusing on enhanced body
defense and the detection of pre-disease states. Zila has three
business units: -- Zila Biotechnology, a research, development and
licensing business specializing in pre-cancer/cancer detection
through its patented Zila Tolonium Chloride and OraTest(R)
technologies. -- Zila Pharmaceuticals, marketer of products to
promote oral health and prevent oral disease, including ViziLite(R)
Plus oral lesion identification kits and Peridex(R) prescription
periodontal rinse. -- Zila Nutraceuticals, manufacturer and
marketer of Ester-C(R) and Ester-E(TM), branded, highly effective
forms of Advanced Protection vitamins C and E. For more information
about Zila, visit www.zila.com. This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based largely on
Zila's expectations or forecasts of future events, can be affected
by inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, margins,
profitability, cash flows and capital needs, the ability of the
Company to maintain required cash flows and cash availability to
implement its business plan and appreciation in the market value of
Zila's common stock. Such factors include, but are not limited to:
increased competition from current competitors and new market
entrants; the Company's ability to maintain, expand, or in certain
cases, regain distribution within new or existing channels of trade
for its products. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Report on Form 10-K
for its fiscal year ended July 31, 2005, filed with the Securities
and Exchange Commission.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jul 2023 to Jul 2024